Madrigal Pharmaceuticals, Inc. - Common Stock — Quarterly Financial Statistics (NASDAQ:MDGL) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -88.89 M-47.05 M79.85 M-133.46 M-167.44 M -268.1 M Cash from investing activities 163.88 M47.86 M-207 M27.58 M192.19 M 60.63 M Cash from financing activities 8.64 M1.74 M236.65 M8.96 M2.33 M 249.67 M Free cash flow -88.89 M-47.05 M79.85 M-133.46 M-167.44 M -268.1 M

News

Viking Therapeutics: Drugs Are In The Pipeline, But Profitability Is Still Unproven (VKTX)

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Is Altimmune Worth Buying Ahead of 2026 Catalysts?

Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?

Madrigal Pharmaceuticals Stock Could Become The Next Vertex (NASDAQ:MDGL)

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT Stock: What Pemvidutide Means for MASH, AUD and ALD

Is Altimmune a Buy Before Phase III MASH Starts in 2026?